Patent · US Active

Codon-optimized lentiviral vector for stem cell reprogramming

US10201597B2 · kind B2 · utility

0Cited by

0References

21Claims

0Family size

Assignee

The Regents of the University of California · US

Inventors

Antoni Ribas · Los Angeles, US
Richard KOYA · Williamsville, US
Thinle Chodon · Buffalo, US

Key dates

Filing date	Sep 29, 2015
Grant date	Feb 12, 2019
Priority date	—
Expiry date	Jan 28, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2800/22
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to methods and materials that can be used to product cytotoxic T cells that target cancer cells expressing the cancer-testis antigen NY ESO-1. Illustrative embodiments of the invention include peripheral blood stem cells transduced with a lentiviral vector that comprises a codon optimized TCR alpha and beta chain polypeptides specific for NY ESO-1. These gene-modified cells are useful, for example, in a hematopoietic stem cell transplantation setting to treat patients diagnosed with NY ESO-1 positive cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.